Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2011-03-15
2011-03-15
Gitomer, Ralph (Department: 1657)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C530S389200
Reexamination Certificate
active
07906302
ABSTRACT:
This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject.
REFERENCES:
patent: 5877396 (1999-03-01), Ravetch et al.
patent: 5911988 (1999-06-01), Brownell et al.
patent: 5997865 (1999-12-01), Bennett et al.
patent: 6576812 (2003-06-01), Longley
patent: 6977159 (2005-12-01), Longley
patent: 6989248 (2006-01-01), Longley
patent: 7449309 (2008-11-01), Longley
patent: 2003/0077282 (2003-04-01), Bigler et al.
patent: 2006/0216282 (2006-09-01), Longley
Anderson, D.M., et al. (1990) “Molecular Cloning of Mast Cell Growth Factor, a Hematopoietin That Is Active in Both Membrane Bound and Soluble Forms,” Cell 63:235-243.
Bradl, M., et al. (1991) “Clonal coat color variation due to a transforming gene expressed in melanocytes of transgenic mice,” Proc. Nat. Acad. Sci. USA 88:6447-6451.
Costa, J.J., et al. (1996) “Recombinant Human Stem Cell Factor (Kit Ligand) Promotes Human Mast Cell and Melanocyte Hyperplasia and Functional Activation In Vivo,” J. Exp. Med. 183:2681-2686.
Funasaka, Y., et al. (1992) “c-Kit-Kinase Induces a Cascade of Protein Tyrosine Phosphorylation in Normal Human Melanocytes in Response to Mast Cell Growth Factor and Stimulates Mitogen-Activated Protein Kinase But is Down-Regulated in Melanomas,” Mol. Biol. Cell 3:197-209.
Furitsu, T., et al. (1993) “Identification of Mutations in the Coding Sequence of the Proto-oncogenec-kitin a Human Mast Cell Leukemia Cell Line Causing Ligand-Independent Activation of c-kitProduct,” J. Clin. Invest. 92:1736-1744.
Grichnik, J.M., et al. (1995) “Human recombinant stem-cell factor induces melanocytic hyperplasia in susceptible patients,” J. Am. Acad. Dermol. 33:577-583.
Hamann, K., et al. (1995) “Expression of stem cell factor in cutaneous mastocytosis,” Br. J. Dermatol. 133:203-208.
Harrist, T.J., et al. (1995) “Recombinant human stem cell factor(SCF) (c-kit ligand) promotes melanocyte hyperplasia and activation in vivo,” Lab. Invest. 72:48A.
Hirobe, T. (1984) “Histochemical Survey of the Distribution of the Epidermal Melanoblasts and Melanocytes in the Mouse During Fetal and Postnatal Periods,” Anat. Rec. 208:589-594.
Longley, J., et al. (1995) “The mast cell and mast cell disease,” J. Am. Acad. Dermatol. 32:545-561.
Longley, B.J., Jr., et al. (1993) “Altered Metabolism of Mast-Cell Growth Factor (c-kitLigand) in Cutaneous Mastocytosis,” N. Engl. J. Med. 328:1302-1307.
Longley, B.J., et al. (1996) “Somatic c-KITactivating mutation in urticaria pigmentosa and aggressive mastocytosis: establisHment of clonality in a human mast cell neoplasm,” Nat. Genet. 12:312-314.
Lu, H.S., et al. (1991) “Amino Acid Sequence and Post-translation Modification of Stem Cell Factor Isolated from Buffalo Rat Liver Cell-conditioned Medium,” J. Biol. Chem. 266:8102-8107.
Nishikawa, S., et al. (1991) “In utero manipulation of coat color formation by a monoclonal anti-c-kit antibody: two distinct waves of c-kit-dependency during melanocyte development,” EMBO J. 10:2111-2118.
Okura, M., et al. (1995) “Effects of Monoclonal Anti-c-Kit Antibody (ACK2) on Melanoctes in Newborn Mice,” J. Invest. Dermatol. 105:322-328.
Weiss, R.R., et al. (1995) “Human Dermal Endothelial Cells Express Membrane-Associated Mast Cell Growth Factor,” J. Invest. Dermatol. 104:101-106.
Tsai, M., et al. (1991) “The Rat c-kit Ligand, Stem Cell Factor, Induces the Development of Connective Tissue-type and Mucosal Mast Cells In Vivo. Analysis by Anatomical Distribution, Histochemistry, and Protease Phenotype,” J. Exp. Med. 174:125-131.
Vassar, R., et al. (1989) “Tissue-specific and differentiation-specific expression of a human K14 keratin gene in transgenic mice,” Proc. Natl. Acad. Sci. USA 86:1563-1567.
Williams, D.E., et al. (1990) “Identification of a Ligand for the c-kit Proto-Oncogene,” Cell 63:167-174.
Yarden, Y., et al. (1987) “Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand,” EMBO J. 6:3341-3351.
Yoshida, H., et al. (1996) “Distinct stages of melanocyte differentiation revealed by analysis of nonuniform pigmentation patterns,” Development 122:1207-1214.
Yoshida, H., et al. (1996) “Neural and Skin Cell-Specific Expression Pattern Conferred by Steel Factor Regulatory Sequence in Transgenic Mice,” Dev. Dyn. 207:222-232.
Zsebo, K.M., et al. (1990) “Stem Cell Factor Is Encoded at the S1 Locus of the Mouse and Is the Ligand for the c-kit Tyrosine Kinase Receptor,” Cell 63:213-224.
Houdebine, L.M. (1994) “Production of pharmaceutical proteins from transgenic animals,” J. Biotechnol. 34:269-287.
Kappel, C.A., et al. (1992) “Regulating gene expression in transgenic animals,” Curr. Opin. Biotechnol. 3:548-553.
Sigmund, C.D. (2000) “Viewpoint: Are Studies in Genetically Altered Mice Out of Control?” Arterioscler. Thromb. Vasc. Biol. 20:1425-1429.
Wall, R.J. (1996) “Transgenic Livestock: Progress and Prospects for the Future,” Theriogenology 45:57-68.
Communication, including Notice to Comply issued Apr. 23, 2002 in connection with U.S. Appl. No. 09/306,143, filed May 6, 1999.
Communication, including Notice to Comply issued Oct. 2, 2002 in connection with U.S. Appl. No. 09/306,143, filed May 6, 1999.
Facsimile dated Dec. 13, 2002 in connection with U.S. Appl. No. 09/306,143, filed May 6, 2003.
Notice of Allowance issued Dec. 20, 2002, including Examiner's Amendment in connection with U.S. Appl. No. 09/306,143, filed May 6, 1999.
Office Action issued Apr. 11, 2001 in connection with U.S. Appl. No. 09/306,143, filed May 6, 1999.
Office Action issued Aug. 2, 2001 in connection with U.S. Appl. No. 09/306,143, filed May 6, 1999.
Office Action issued Jul. 13, 2000 in connection with U.S. Appl. No. 09/306,143, filed May 6, 1999.
Ando A., et al. (1993) “Effects on chronic treatment with the c-kit ligand, stem cell factor on immunoglobulin E-dependant anaphylacis, genetically mast cell-deficient SI/SId mice acquire anaphylactic responsiveness, but the congenic normal mice do not exhibit augmented responses,” J. Clin. Invest. 92:1639-49.
Askenase P., et al. (1983) “Defective elicitation of delayed-type hypersensitivity in W/Wv and SI/Sid mast cell deficient mice 1” The Journal of Immunology 6:2687-2693.
Bischoff, S.C., et al. (1992) “c-kit ligand: a unique potentiator of mediator release by human lung mast cells,” J. Exp. Med. 175:237-44.
Coleman, J.W., et al. (1993) “Regulation of mouse peritoneal mast cell secretory function by stem cell factor, IL-3 or IL-4” J. Immunol. 150:556-62.
Columbo M. et al. (1992) “The human recombinant c-kit receptor ligand” J. of Immolo. 149(2)599-608.
Devinney R., et al. (1990) “Establishment of two dog mastocytoma cell lines in continuous culture,” Am. J. Respr. Cell Mol. Biol. 3:413-420.
Dunn T.B., et al. (1957) “A transplant mast-cell neoplasm in the mouse,” J. Natl. Cancer Inst. 18:587-601.
Galli S.J., et al. (1995) “Undiminished immunologic tolerance to contact sensitivity in mast cell-deficient w/wv and s1/s1d mice 1,” The Journal of Immunology 2:879-885.
Hirota S., et al. (1998) “Gain of function mutations of c-kit in human gastrointestinal stromal tumors,” Science 279:577-580.
Kitayama H., et al. (1995) “Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines,” Blood 85:790-798.
Lazarus S.C., et al. (1986) “Isol
Cooper & Dunham LLP
Gitomer Ralph
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Methods of preventing or treating contact dermatitis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of preventing or treating contact dermatitis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of preventing or treating contact dermatitis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2758891